Y-Intercept (HK)’s Karyopharm Therapeutics KPTI Stock Holding History

Y-Intercept (HK)’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10,375	Closed	-$101K	–	1852
2026 Q2	$101K	Buy	+10,375	New	+$90K	﹤0.01%	1613
2024 Q3	–	Sell	-27,397	Closed	-$357K	–	1571
2024 Q2	$357K	Buy	+27,397	New	+$454K	0.02%	966
2023 Q3	–	Sell	-2,262	Closed	-$60.7K	–	1344
2023 Q2	$60.7K	Buy	+2,262	New	+$97.4K	0.01%	1186
2023 Q1	–	Sell	-1,006	Closed	-$51.3K	–	1361
2022 Q4	$51.3K	Buy	1,006 +315	+46%	+$21.8K	0.01%	917
2022 Q3	$56.6K	Buy	+691	New	+$51.6K	0.01%	906

Other funds holding KPTI

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $355M AUM

MLA

MB, Levis & Associates Center Valley, Pennsylvania $273M AUM 8.08% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

WBC

West Branch Capital Amherst, Massachusetts $442M AUM 32.59% 1-Year Est. Return

Y-Intercept (HK)'s KPTI Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Karyopharm Therapeutics (KPTI) in Q3 2026, closing a stake of 10,375 shares — an estimated $101K sold.

Y-Intercept (HK) first reported a position in KPTI in Q3 2022 and held it in 5 quarters. The position peaked at $357K in Q2 2024. 8 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

Y-Intercept (HK) reported no remaining Karyopharm Therapeutics position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 10,375 Karyopharm Therapeutics shares in Q3 2026, an estimated $101K.
Y-Intercept (HK) first reported a position in Karyopharm Therapeutics in Q3 2022 and held it in 5 quarters.
Y-Intercept (HK)'s Karyopharm Therapeutics position peaked at $357K in Q2 2024.
8 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.